Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Top Cited Papers
- 11 January 2018
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 378 (2), 158-168
- https://doi.org/10.1056/nejmra1703481
Abstract
The wide range of immune-related adverse effects associated with immune checkpoint blockade can complicate this effective therapy and limit its use in patients with cancer. This review surveys the adverse effects and their management.Keywords
This publication has 76 references indexed in Scilit:
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantationBlood, 2009
- Dose-related patterns of glucocorticoid-induced side effectsAnnals Of The Rheumatic Diseases, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular AutoimmunityThyroid®, 2005
- CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.The Journal of Experimental Medicine, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian populationJournal of Clinical Endocrinology & Metabolism, 1995
- REITER'S DISEASE AND HL-A 27The Lancet, 1973